<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541475</url>
  </required_header>
  <id_info>
    <org_study_id>112063</org_study_id>
    <secondary_id>GSK IIT</secondary_id>
    <nct_id>NCT01541475</nct_id>
  </id_info>
  <brief_title>Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder</brief_title>
  <official_title>Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is being conducted in patients with major depression. The study aims to 1)
      investigate the combined effects of selective serotonin reuptake inhibitor (SSRI) and
      bupropion compared to SSRI alone on the improvements of depressive symptoms, fatigue,
      hypersomnia, and neurocognitive functions, 2) observe structural/functional/chemical changes
      using magnetic resonance imaging (MRI), 3) and examine a relationship between the
      improvements of depressive symptoms, fatigue, and hypersomnia and the neural changes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Depressive Symptom Scores at 8 Weeks</measure>
    <time_frame>Baseline and at 8 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Depressive Symptom Scores at 4 Weeks</measure>
    <time_frame>Baseline and at 4 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Depressive Symptom Scores at 1 Week</measure>
    <time_frame>Baseline and at 1 Week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>1 Week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Function as Expressed as Z Scores Transformed Using the Control Group Mean and Distribution Values at 8 Weeks</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Brain Structure and Function, Analyzed Using the Computational Approach</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fatigue Severity Scale scores</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram + Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion, Escitalopram</intervention_name>
    <description>Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg</description>
    <arm_group_label>Escitalopram + Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 20 and 65

          -  Diagnosis of major depressive disorder (MDD) as assessed by the Structured Clinical
             Interview for DSM-IV (SCID-IV)

          -  Individuals who provided written consent for participation.

        Exclusion Criteria:

          -  Presence of any major physical or neurological illness (e.g., head trauma, epilepsy,
             seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease,
             narrow-angle glaucoma, drug hypersensitivity, etc.)

          -  Diagnosis of any Axis I disorder other than MDD or presence of symptoms requiring
             hospitalization

          -  Intelligence quotient (IQ) below 80

          -  Contraindications to magnetic resonance imaging (e.g., pacemaker implantation,
             claustrophobia, etc.)

          -  Unstable medical illness or other abnormalities observed at the screening or
             laboratory tests

          -  Women who are pregnant, breastfeeding, or planning pregnancy

          -  Allergy or tolerance to the clinical trial medication

          -  Presence of any physical illness that contraindicates the clinical trial medication
             (e.g., epilepsy, history of uncontrollable narrow-angle glaucoma)

          -  Use of psychoactive medications that may affect brain imaging findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ehwa W. univ hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Biomedical Research Institute</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

